Core Insights - BGI is one of the largest genomics companies globally, operating DNA sequencing laboratories and processing genetic data for various sectors [2][3] - Concerns are rising regarding BGI's potential to surpass Huawei in scale and implications, particularly in the realm of genetic data collection [3][8] - U.S. officials express fears about the implications of BGI's operations, including the potential for military applications and genetic enhancement [5][7] Company Overview - BGI originated as the Beijing Genomics Institute, closely linked to China's national genome projects, and has evolved into a global commercial entity [1] - The company provides services such as DNA sequencing, prenatal testing, cancer screening, and large-scale population genetic analysis [1] Market Position - BGI has established a significant global presence, processing genetic data for hospitals, pharmaceutical companies, and researchers across numerous countries [2] - The company is perceived as a strategic asset in the biotechnology sector, with its genetic data collection capabilities raising concerns about a "DNA arms race" [7] Political and Security Concerns - U.S. lawmakers have warned about BGI's close ties to the Chinese Communist Party and military, suggesting that commercial data is often intertwined with state security needs [6] - Senator Mark Warner emphasizes the need for vigilance regarding BGI's data collection practices, which could have far-reaching implications for national security [7][12] Legislative Actions - The U.S. Congress is considering the BIOSECURE Act to limit the operations of Chinese biotech firms like BGI within the U.S. [13] - BGI has publicly stated that it complies with regulations and does not access Americans' personal data [13] Technological Competition - Warner draws parallels between BGI's rapid growth and Huawei's rise, highlighting the need for the U.S. to adapt its intelligence and regulatory approaches to address emerging biotech threats [12][14] - The U.S. intelligence community is criticized for its slow response to the biotech challenge, with calls for a more advanced approach to monitoring technological advancements [14][15]

MONTREAL--(BUSINESS WIRE)--Birks Group Inc. (the "Company†or "Birks Group†) (NYSE American: BGI), today reported its financial results for the twenty-six-week period ended September 27, 2025. Highlights All figures presented herein are in Canadian dollars. For the twenty-six-week period ended September 27, 2025 ("Fiscal 2026†), the Company reported net sales of $93.1 million, an increase of $13.0 million or 16.2% from the comparable prior period ended September 28, 2024 ("Fiscal 2025†). Comparable sto ...

MONTREAL--(BUSINESS WIRE)--Birks Group Inc. (the "Company†or "Birks Group†) (NYSE American: BGI), today announced that the board of directors of the Company (the "Board†) has recommended the appointment of Grant Thornton S.E.N.C.R.L. ("Grant Thornton†) as auditors of the Company for the Company's fiscal year ending March 28, 2026 ("fiscal year 2026†). KPMG LLP ("KPMG†) has served as the Company's independent auditors since January 25, 2000. On July 29, 2025, following the issuance of KPMG's au. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 29, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission file number: 001-32635 BIRKS GROUP INC. (Translation of Registrant's name into English) 2020 Robert Bourassa Suite 200 Montreal, Québec Canada H3A 2A5 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under co ...

Exhibit 99.1 | --- | --- | --- | --- | |-------|-------|-------|--------------------------------------------------------------------------------| | | | | | | | | | | | | | | Company Contact: | | | | | Katia Fontana | | | | | Vice President and Chief Financial Officer | | | | | (514) 397-2592 | | | | | For all press and media inquiries, please contact: Press@birks.com | BIRKS GROUP INC. REPORTS FISCAL 2024 RESULTS Montreal, Quebec. July 16, 2024 - Birks Group Inc. (the "Company" or "Birks Group") (NYSE Ameri ...

As part of our commitment to continuous, on-the-job training, we have established "Birks University", a formalized system of in-house training with a primary focus on client service, selling skills and product knowledge that involves extensive training, the use of detailed operational manuals, in-store mentorship programs and a leading edge product knowledge program which includes on-line quizzes. In addition, we conduct in-house training seminars on a periodic basis and administer training modules with aud ...

MONTREAL--(BUSINESS WIRE)--Birks Group Inc. (the “Company” or “Birks Group”) (NYSE American: BGI), reported its sales results for the 8 week interim sales period ended December 30th, 2023 (the “FY2024 Holiday Period”) resulting in an increase of 8.1% in net sales as compared to the same period in FY2023. Comparable store sales for the FY2024 Holiday Period increased by 3.0% as compared to the same period in FY2023. The 8.1% increase in net sales for the FY2024 Holiday Period, as compared to the same period ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission file number: 001-32635 BIRKS GROUP INC. (Translation of Registrant's name into English) | --- | |-----------------------------------------------------------| | | | | | | | 2020 Robert Bourassa | | Suite 200 | | Montreal, Québec | | Canada | | H3A 2A5 (Address of principal execut ...

Exhibit 99.1 BIRKS GROUP REPORTS FISCAL 2023 RESULTS All figures presented herein are in Canadian dollars. Mr. Jean-Christophe Bédos, President and Chief Executive Officer of Birks Group, commented: "During fiscal 2023, we achieved a 2.9% growth in comparable store sales and an increase in our average sales transaction value, as our core business continued to grow despite being confronted with significant economic headwinds including on-going inflationary pressures and a sense of uncertainty that permeated ...